Find out what led biotech to a situation where women are underrepresented in clinical trials and how the industry is ...
Alzamend Neuro (ALZN) announced its plans to initiate a highly anticipated phase II clinical study of AL001 for treatment of patients with PTSD ...
A new batch of neflamapimod capsules led to increased plasma drug concentrations and demonstrated improvement (p<0.001 vs. old capsules; p=0.003 vs. placebo) on the primary outcome measure, change ...
The combination demonstrated non-inferiority to comparator antiretroviral therapies, meeting the primary efficacy success ...
Alzamend Neuro plans a Phase 2 trial of AL001 for PTSD in late 2025, aiming for better lithium delivery, improved safety, and ...
Promising Nonalcoholic Steatohepatitis Therapies such as AZD2693, Saroglitazar Magnesium 4 mg, Semaglutide (SEMA), Cilofexor ...
"Receiving the FDA's clearance to proceed with our Phase 2 clinical trial for TPST-1495, our second clinical program, in FAP marks an important step forward in developing new treatment options for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results